Clinical Trial Update: Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19 [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating inhaled nitric oxide for mild to moderate COVID-19 was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia
• Respiratory Distress Syndrome

Drugs mentioned

• Nitric Oxide Gas Inhalation Therapy (nitric oxide inhalation)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Coronavirus Infections, Pneumonia, Viral | Phase 2 | Status: TERMINATED | Results posted: 2026-03-23